SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs rally to fresh highs is being tied to Goldman Sachs upgrade to Buy, which cited opportunities in sovereign AI and customized software. Bulls are celebrating the breakout and AI-growth outlook, while skeptics argue the valuation is stretched and warn of a pullback.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Repeated analyst downgrades and price-target cuts amid a steep, volatile pullback are dominating discussion ahead of AppLovins upcoming results. Bulls argue the decline overlooks the companys growth and cash generation, while frustrated holders debate whether the weakness reflects excessive analyst pessimism or genuine risks to the outlook.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG is drawing attention as a Bitcoin-native Runes memecoin, with holders promoting its Bitcoin connection and community-driven launch while saying they are accumulating through a prolonged pullback. Critics counter that trading is thin and the token is heavily hyped, leaving the discussion divided between long-term conviction and concerns about liquidity and downside risk.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on TG Therapeutics scheduled data presentations at MSToronto, especially a late-breaking oral presentation of initial Phase 1 azer-cel findings in progressive MS, alongside BRIUMVI data. Traders view the presentation slot as encouraging and are positioning for potential news, but the results are not yet known; discussion also points to upcoming subcutaneous BRIUMVI data and remains divided between bullish catalyst expectations and frustration with choppy trading.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys partnership with Meta to let its Muse AI agent complete purchases through Shop Pay is fueling optimism that Shopify can benefit from agentic commerce rather than be displaced by AI, alongside enthusiasm about strong growth and bullish analyst views. Traders are also debating whether the rally has outrun fundamentals and may pull back, with some questioning how quickly AI-driven shopping can generate meaningful revenue.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is drawing attention alongside a reported NIH-backed effort to accelerate personalized cancer vaccines, a theme traders connect to its V940 program with Moderna and Keytruda. The initiative is an early research push, not a guarantee of near-term revenue, and some discussion also focuses on Mercks prior positive Phase 3 melanoma-vaccine results.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

FDA review documents showing a comparatively weak response rate for daraxonrasib in the KRAS G12D pancreatic-cancer subgroup have raised fresh concerns about efficacy and competition from more selective RAS inhibitors. Traders debate whether the subgroup response data signal a real weakness or are less important than the drugs broader survival results, while some view the selloff as an overreaction.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

BNB is drawing attention for a choppy rebound within a consolidation range, with repeated technical commentary describing balanced trading and nearby resistance. Traders are split between expecting further upside and viewing the move as a bull trap that could give way to a pullback.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoins rally is drawing attention amid speculation about a proposed Grayscale ETF and demand for its proof-of-human identity system as AI agents and bots grow. Bulls see the AI-identity narrative and buying interest as supportive, while skeptics point to sharp volatility and question the projects value and promotional hype.

dogwifhat (WIF) is a Solana-based memecoin featuring a Shiba Inu dog wearing a pink knitted hat that has become a central figure in the 2024-2026 market. Originally launched anonymously in late 2023, the project operates on a decentralized, community-driven model with no formal venture capital backing or complex tokenomics. It represents a cultural phenomenon on the Solana blockchain that celebrates whimsy and simplicity over technical complexity, focusing on its identity as a playful mascot for the digital finance era. The project’s main value proposition is its "Pure Meme Identity," as it maintains a strict focus on its meme origins without forced utility or a pivot toward DeFi and gaming.  The project embodies the community-driven nature of the Solana ecosystem, prioritizing "vibes" and meme-sharing as its primary growth drivers. It follows a "hat stays on" philosophy, maintaining a singular focus on its core meme rather than building a complex ecosystem. While the project does not have a formal governance structure or DAO, decisions are largely driven by social consensus among the community and key influencers. Notable community initiatives include the "Sphere Wif Hat" campaign, which raised nearly $700,000 in USDC in March 2024 to put the mascot on the Las Vegas Sphere. However, after a year of negotiations and delays, organizers officially abandoned the advertisement on March 31, 2025, and initiated a full refund process for donors.  The initial team behind dogwifhat remains anonymous, which is a standard practice within the memecoin sector. The coin's narrative is heavily influenced by prominent crypto personalities, most notably Ansem, who was a key figure in the project's early viral growth and subsequent marketing initiatives. Regarding integrations, WIF has deep liquidity across major Solana decentralized exchanges like Jupiter and Raydium, is available on the Unichain network via official contract bridging, and is listed on major centralized exchanges including Binance, Coinbase, Kraken, and Bybit.  WIF is a purely speculative asset whose value is primarily driven by community sentiment and meme culture rather than traditional utility. It was launched without a presale or significant venture capital allocation, meaning the token's supply is fully circulating. The project has achieved a "blue chip" status in the memecoin space, often serving as a beta-play for the broader health of the Solana ecosystem. No native decentralized applications or trading bots have been officially launched by the core team, as the project maintains its focus on its identity as "literally a dog wif a hat".

dogwifhat

WIF is drawing attention for persistent selling and prolonged sideways trading, with many traders frustrated that brief gains fade and the token struggles to recover. Some see a potential bottom and are buying dips, while claims that trading is being manipulated remain speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Brief Healthcare: Medline Inc. (MDLN): Largest Cash Raise IPO Since 2021's Rivian Brings End of Year Opportunity and more

In this briefing: Medline Inc. (MDLN): Largest Cash Raise IPO Since 2021's Rivian Brings End of Year Opportunity Medline (MDLN US): Global & US Index Inclusion; Overestimated Valuation? Medical Data Vision (3902 JP): Nippon Life’s Rumoured Tender Offer at 3x the Last Close [Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem 1. Medline Inc. (MDLN): Largest Cash Raise IPO Since 2021's Rivian Brings End of Year Opportunity Medline’s IPO is poised to be 2025’s largest, with a potential $5.4bn raise, positioning it as a key bridge deal into the 2026 IPO pipeline. Strong anchor demand and an oversubscribed book highlight investor appetite for scaled, mature healthcare platforms with durable cash flows.` Proceeds will materially reduce leverage, supporting a more balanced capital structure and reinforcing Medline’s long-term investment appeal. 2. Medline (MDLN US): Global & US Index Inclusion; Overestimated Valuation?

Brief India: Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (15 Dec) and more

In this briefing: Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (15 Dec) 2026 High Conviction: Tenneco Clean Air The Thermal Vs Renewable Debate: JSW Energy - 2026 High Conviction Idea APAC Healthcare Weekly (December 14) – China NRDL, Fosun Pharma, SanBio, Peptidream, Zydus Life Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem 1. Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (15 Dec) Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities. Opportunity: Currently eight pair trade opportunities across four markets and five sectors persist. Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs. 2. 2026 High Conviction: Tenneco Clean Air Tenneco Clean Air India Ltd (1880671D IN) is part of the Tenneco Group, a U.S.-headquartered global Tier I automotive component supplier.

Brief India: 2026 High Conviction: Tenneco Clean Air and more

In this briefing: 2026 High Conviction: Tenneco Clean Air The Thermal Vs Renewable Debate: JSW Energy - 2026 High Conviction Idea APAC Healthcare Weekly (December 14) – China NRDL, Fosun Pharma, SanBio, Peptidream, Zydus Life Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem JK Lakshmi Cement: Volume Momentum Remains Strong. Maintain BUY 1. 2026 High Conviction: Tenneco Clean Air Tenneco Clean Air India Ltd (1880671D IN) is part of the Tenneco Group, a U.S.-headquartered global Tier I automotive component supplier. It designs and manufactures clean air, powertrain, and suspension solutions for Indian OEMs and export markets. Since its listing, the stock is up 19%, but there is still upside potential. 2. The Thermal Vs Renewable Debate: JSW Energy - 2026 High Conviction Idea JSW has shown strong growth in generation capacity, with plans to double it to 30GW by 2030. The company is also venturing into ancillaries like battery assembly and hydrogen production.

Brief Healthcare: Medical Data Vision (3902 JP): Nippon Life’s Rumoured Tender Offer at 3x the Last Close and more

In this briefing: Medical Data Vision (3902 JP): Nippon Life’s Rumoured Tender Offer at 3x the Last Close [Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem Primer: Artrya (AYA AU) - Dec 2025 RadNet: Focusing On The Future of Imaging With AI Adoption and Strategic Partnerships; Will It Pan Out? 1. Medical Data Vision (3902 JP): Nippon Life’s Rumoured Tender Offer at 3x the Last Close The Nikkei reports that Nippon Life Insurance will launch a tender offer for Medical Data Vision (3902 JP) at a valuation up to JPY60 billion. If the valuation refers to market cap, the offer is JPY1,500, a 225% premium to the last close of JPY462. If it relates to EV, the offer price is JPY1,550. Despite the staggering premium, it does not represent an all-time high (share price traded higher in November 2021). Nevertheless, a binding proposal would be a done deal. 2. [Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn Medical Data Vision (3902 JP) was IPOed in 2014.

Brief Growth Ideas: Primer: Shikoku Electric Power Co (9507 JP) - Dec 2025 and more

In this briefing: Primer: Shikoku Electric Power Co (9507 JP) - Dec 2025 Primer: Gumi Inc (3903 JP) - Dec 2025 Rohm (6963 JP): Renewed Growth, Conservative Guidance & Reasonable Valuation Wealthfront Corporation (WLTH): Financial Platform Falls Flat Despite Heavy Pre-IPO Interest Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem 1. Primer: Shikoku Electric Power Co (9507 JP) - Dec 2025 Shikoku Electric Power is demonstrating a significant financial turnaround, with net income rebounding strongly in the latest fiscal years after a loss in FY2023, driven by operational efficiencies and a favorable regulatory environment. The company is strategically expanding its renewable energy portfolio, with a target to increase capacity to 500MW by FY2030 and 2GW by FY2050, focusing on solar (including floating solar), biomass, and wind power. The stable operation of its sole nuclear reactor, Ikata Unit 3, is a critical earnings driver, though it remains subject to regulatory oversight, legal challenges, and periodic maintenance shutdowns.

Brief Healthcare: [Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn and more

In this briefing: [Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem Primer: Artrya (AYA AU) - Dec 2025 RadNet: Focusing On The Future of Imaging With AI Adoption and Strategic Partnerships; Will It Pan Out? Roivant Sciences: From Batoclimab Breakthroughs to Global Trials—A Rising Contender in Autoimmune Therapeutics! 1. [Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn Medical Data Vision (3902 JP) was IPOed in 2014. MitCorp sold. Others sold. Fujifilm and Medipal stayed in. The stock ran up. SBI bought from Fujifilm in Nov2020 at ¥2355. The stock fell, SBI bought more in 2021-2022. Then it fell more in 2023 and SBI bought more, then fell more in 2024 and SBI bought more. The Nikkei reports today that Nippon Life will announce a TOB on 15 December with a max price of ¥60bn (242% premium), which coincidentally would bring SBI close to breakeven. 2.

Brief Growth Ideas: Primer: Gumi Inc (3903 JP) - Dec 2025 and more

In this briefing: Primer: Gumi Inc (3903 JP) - Dec 2025 Rohm (6963 JP): Renewed Growth, Conservative Guidance & Reasonable Valuation Wealthfront Corporation (WLTH): Financial Platform Falls Flat Despite Heavy Pre-IPO Interest Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem Primer: The Walt Disney Co (DIS US) - Dec 2025 1. Primer: Gumi Inc (3903 JP) - Dec 2025 Strategic Pivot to Web3 and Metaverse: Gumi is aggressively shifting its focus from a reliance on hit-driven mobile games to becoming a comprehensive Web3 enterprise, underscored by strategic partnerships with Square Enix and SBI Holdings, and significant investments in cryptocurrencies like XRP and Bitcoin. Financial Volatility and Restructuring: The company has experienced significant financial turbulence, with a substantial net loss in FY24 driven by underperforming titles, leading to the discontinuation of flagship games, workforce reductions, and a halt in the development of high-risk original titles.

Brief Growth Ideas: Rohm (6963 JP): Renewed Growth, Conservative Guidance & Reasonable Valuation and more

In this briefing: Rohm (6963 JP): Renewed Growth, Conservative Guidance & Reasonable Valuation Wealthfront Corporation (WLTH): Financial Platform Falls Flat Despite Heavy Pre-IPO Interest Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem Primer: The Walt Disney Co (DIS US) - Dec 2025 2026 IPOs Pipeline (USA and Europe) 1. Rohm (6963 JP): Renewed Growth, Conservative Guidance & Reasonable Valuation Sales are growing again and the company has turned profitable with capacity utilization up and costs down. Guidance for 2H of FY Mar-26 looks conservative. Sales of power devices is rising after a long period of weakness, supported by auto, industrial and data center related demand. Projected valuations are once again reasonable. The share price should continue to trend upwards. 2. Wealthfront Corporation (WLTH): Financial Platform Falls Flat Despite Heavy Pre-IPO Interest Wealthfront priced 34.6mm shares at $14.00, top of range, and opened flat before closing up 1.4% after a volatile first session.

Brief India: APAC Healthcare Weekly (December 14) – China NRDL, Fosun Pharma, SanBio, Peptidream, Zydus Life and more

In this briefing: APAC Healthcare Weekly (December 14) – China NRDL, Fosun Pharma, SanBio, Peptidream, Zydus Life Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem JK Lakshmi Cement: Volume Momentum Remains Strong. Maintain BUY Company Update: Tata Steel Ltd - 12 Th December, 2025 Thematic Report On India’s Valuation Reset: How Markets Are Repricing Growth Heading Into 2026 1. APAC Healthcare Weekly (December 14) – China NRDL, Fosun Pharma, SanBio, Peptidream, Zydus Life China has published 2025 National Reimbursement Drug List, which will be officially implemented nationwide on January 1, 2026. The list added 114 new drugs, including 50 Class 1 innovative drugs. Fosun Pharmaceutical subsidiary inked exclusive global collaboration and license agreement with Pfizer for weight loss drug candidate YP05002. SanBio obtained partial change approval to the marketing authorization for Akuugo. PeptiDream achieved milestone of nominating a clinical development candidate from collaboration program with Asahi Kasei.

Brief Equities Bottom-Up: Amdocs: Looking To Reinvent Telecom Software With Agentic AI—Here’s Why It Matters! and more

In this briefing: Amdocs: Looking To Reinvent Telecom Software With Agentic AI—Here’s Why It Matters! Shift4 Payments: Can This Powerful Global Blue Expansion Unlock a New Wave of Growth? Pinterest + tvScientific = Ad Game Changer? The Synergies You Need to Know! Taiwan Dual-Listings Monitor: TSMC Historically High Premium Cracks; ChipMOS & CHT Opportunities Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem 1. Amdocs: Looking To Reinvent Telecom Software With Agentic AI—Here’s Why It Matters! Amdocs reported its financial performance for the fourth quarter and full fiscal year of 2025, signaling key trends within the company and its strategic direction. On a pro forma constant currency basis—accounting for the phaseout of certain low-margin noncore business activities—Amdocs achieved revenue growth of 3.1% for the fiscal year. In the fourth quarter, revenue reached $1.15 billion, showing a 2.8% increase compared to the previous year in pro forma constant currency terms. 2.

Max India Ltd. engages in the provision of senior living communities, management, and consultancy services. It operates through the following segments: Business Investments, Senior Living, Assisted Care, and Others. The Business Investments segment is represented by treasury investments, rental from investment property and functional support services to group companies. The Senior Living segment refers to the two of the company’s subsidiaries involved in the business of senior living. The Assisted Care segment caters to the seniors by providing care at home services and care homes facilities. The company was founded by Analjit Singh on January 23, 2019 and is headquartered in Gurugram, India.

Current Price	156.50
Prev Close	159.00
Open	158.00
Dividend Yield	0.00%
50-Day Moving Average	154.72
Beta	0.04
Avg. Volume	70,853.33
PE Ratio	-6.12

52-Week High	225.01
52-Week Low	120.00
Market Capitalization	8.94B
EPS (Annual)	-23.85
Price to Book	1.99
Revenue Per Employee	1.38M

Feed

News

Sentiment

Fundamentals

Info

MAXIND.NSE Fundamentals